报价延迟最少15分钟:2026/06/06 03:38 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.92 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.57/-0.63
|
|
企业价值
18.87M
|
| 资产负债 |
|
每股账面净值
0.33
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
3.73
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications. |
